Mensah, K; Mocanu, MM; Yellon, DM; (2006) The beneficial effects of chronic statin treatment are not mediated by direct effects on the ischaemic myocardium. In: Kimchi, A, (ed.) Advances in Heart Disease. (pp. 271 - 275). MEDIMOND S R L
Full text not available from this repository.
1) Does chronic statin treatment limit infarct and 2) is acute treatment beneficial with chronic therapy. Rats were gavaged daily for two weeks with 1% methylcellulose or atorvastatin 20 mg/kg, 40mg/kg or 80 mg/kg, their hearts isolated and subjected to 35 minutes of ischemia (Langendoff) and 120 minutes reperfusion. 2 further groups' receiving 20mg/kg and 80 mg/kg atorvastatin gavage were reperfused with 50mmol/ I of atorvastatin for the first 15 minutes. Atorvastatin given chronically did not limit infarct size compared to controls (I/R ratio 54.6%+/- 6.4%) at 20mg/kg, 40mg/kg or 80mg/kg (l/R ratios 58.4%+/- 3.3%, 42.4%+/- 8.5% and 58.4% +/- 5.1% respectively). Atorvastatin 50 mu mol/l produced significant reduction in infarct size (p < 0.05) after chronic gavage with 20mg/kg and 80mg/kg of atorvastatin (I/R ratio 25.67%+/- 5.4% and 24%+/- 6.6% respectively). Chronic treatment with statins does not directly protect the myocardium. Further acute statin at reperfusion protects despite chronic treatment.
|Title:||The beneficial effects of chronic statin treatment are not mediated by direct effects on the ischaemic myocardium|
|Event:||12th World Congress on Heart Disease|
|Dates:||2005-07-16 - 2005-07-19|
|Keywords:||COA REDUCTASE INHIBITORS, CORONARY-HEART-DISEASE, INFARCT SIZE, SIMVASTATIN, PRAVASTATIN, ATORVASTATIN, PRETREATMENT, REPERFUSION, PREVENTION, PROTECTION|
|UCL classification:||UCL > School of Life and Medical Sciences > Faculty of Population Health Sciences > Institute of Cardiovascular Science|
Archive Staff Only: edit this record